Legal Representation
Attorney
Tracy-Gene G. Durkin
USPTO Deadlines
Next Deadline
7 days remaining
Statement of Use Due - Extension 5 Granted
Due Date
August 09, 2025
Application History
46 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 15, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 14, 2025 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Feb 7, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 7, 2025 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Aug 6, 2024 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Aug 6, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 6, 2024 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Aug 6, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 9, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 9, 2024 | NOAC | E | CORRECTED NOA E-MAILED | Loading... |
| Mar 8, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Mar 8, 2024 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
| Feb 27, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Feb 26, 2024 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
| Feb 8, 2024 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
| Feb 8, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 8, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Aug 11, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 9, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 9, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 9, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Feb 11, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 9, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 9, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 9, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 9, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 14, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 14, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 25, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 10, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 26, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 6, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 6, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 6, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Nov 12, 2021 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Nov 12, 2021 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Nov 12, 2021 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Oct 13, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 12, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 12, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 13, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 13, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 13, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 12, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 6, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 9, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for use in the prevention of cancer and tumors; pharmaceutical preparations for use in the prevention of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of infectious, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and biological preparations in the nature of pharmaceutical and biological preparations for the treatment of infectious, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; pharmaceutical preparations and substances for conditioning patients to receive therapies for the treatment of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diagnostic agents, preparations, and substances for medical purposes; reagents for medical use; diagnostic kits comprised of medical diagnostic reagents and assays to test tissue for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; diagnostic kits comprised of medical diagnostic reagents and assays to test bodily fluids for use in the detection of infectious, oncological, inflammatory, immune, auto-immune, genetic, and rare diseases, disorders, and conditions; medical diagnostic assays for testing body fluids; medical diagnostic assays for testing body tissue; diagnostic kits comprised of medical diagnostic assays to test for cell expressions for use in identifying pharmaceutical preparations and therapies for treating medical diseases, disorders, and conditions in humans
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"